Correlation Between Bristol Myers and Eagle Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Eagle Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Eagle Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Eagle Pharmaceuticals, you can compare the effects of market volatilities on Bristol Myers and Eagle Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Eagle Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Eagle Pharmaceuticals.

Diversification Opportunities for Bristol Myers and Eagle Pharmaceuticals

0.52

Correlation Coefficient

Bristol Myers  Eagle Pharmaceuticals

Very weak diversification

The 3 months correlation between Bristol and Eagle is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Eagle Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eagle Pharmaceuticals and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Eagle Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eagle Pharmaceuticals has no effect on the direction of Bristol Myers i.e., Bristol Myers and Eagle Pharmaceuticals go up and down completely randomly.

Pair Corralation between Bristol Myers and Eagle Pharmaceuticals

Considering the 90-day investment horizon Bristol Myers Squibb is expected to under-perform the Eagle Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Bristol Myers Squibb is 2.56 times less risky than Eagle Pharmaceuticals. The stock trades about -0.36 of its potential returns per unit of risk. The Eagle Pharmaceuticals is currently generating about -0.06 of returns per unit of risk over similar time horizon. If you would invest  486.00  in Eagle Pharmaceuticals on February 3, 2024 and sell it today you would lose (46.00) from holding Eagle Pharmaceuticals or give up 9.47% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Eagle Pharmaceuticals

Bristol Myers Squibb

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Eagle Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eagle Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Bristol Myers and Eagle Pharmaceuticals

The main advantage of trading using opposite Bristol Myers and Eagle Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Eagle Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will offset losses from the drop in Eagle Pharmaceuticals' long position.

The idea behind Bristol Myers Squibb and Eagle Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.